Background: Breast cancer is the second leading cause of cancer-related deaths among
women in the Western World.
Method: Upon diagnosis and treatment in the preinvasive state, the five years survival rate levitate up
to 93%, making early detection crucial for dedicative diagnosis and treatment. Currently,
mammography is the most efficacious diagnostic modality. However, this technique does not match
the ultimate sensitivity. Other routinely used biomarkers include tumor size, histological type, nuclear
and cellular characteristics, mitotic index, vascular invasion, hormonal and axillary lymph node status
were not good enough to predict the course of cancer. To date, researchers revealed a change in the
level of some proteinases in breast cancer tissue and reported the role of these proteinases in tumor
aggressiveness and patient response to therapy.
Conclusion: This review summarizes the potential role of serine proteinases (including urokinasedependent
plasminogen activator and kallikreins) and zinc metalloproteinases (including matrix
metalloproteinase and A disintegrin and metalloproteinase) as either a prognostic and/or diagnostic
breast cancer biomarkers. These proteinases plus genetic biomarkers could be implemented in the
development of multiplex bio sensing platform toward early breast cancer detection, diagnosis,
monitor progression and therapeutic success.